Targets › GLRA1
7 programs from 7 companies in 15 trials: 8 Phase 4, 5 Phase 3, 2 Phase 2; Neurology, Cardiovascular, Psychiatry; next expected readout Nov 2026.
Subunit of heteromeric glycine-gated chloride channels. Plays an important role in the down-regulation of neuronal excitability. (UniProt, P23415)
Open in Phaseline: the race on GLRA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Sevoflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 4 | Lung Cancer; Hepatocellular Carcinoma; Ovarian Cancer | Nov 2026 |
| Pharmasoft | Glycine Glycine receptor agonist | GLRA1 | Phase 4 | Ischemic Stroke | Apr 2027 |
| Medical University of Vienna | Desflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 4 | Postoperative Delirium | Dec 2027 |
| Georgia Tsaousi | Desflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 4 | Brain Edema Caused by Drugs | – |
| Xijing Hospital | desflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 3 | Cardiac Surgery | Dec 2028 |
| Sedana Medical | Isoflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 3 | Post-Intensive Care Syndrome; Diabete Mellitus; Sedation; Prevention of Delirium … | – |
| NeuroRx | NRX-101 D-cycloserine (NMDA co-agonist/glycine site modulator) + Lurasidone (5-HT and dopamine ant | GLRA1, HTR2A | Phase 2 | Treatment Resistant Depression | Dec 2027 |
Lung Cancer (1) Hepatocellular Carcinoma (1) Ovarian Cancer (1) Ischemic Stroke (1) Postoperative Delirium (1) Treatment Resistant Depression (1) Cardiac Surgery (1) Brain Edema Caused by Drugs (1) Post-Intensive Care Syndrome (1) Diabete Mellitus (1) Sedation (1) Prevention of Delirium (1)
small molecule (7)
Kaohsiung Medical University Chung-Ho Memorial Hospital (1) Pharmasoft (1) Medical University of Vienna (1) NeuroRx (1) Xijing Hospital (1) Georgia Tsaousi (1) Sedana Medical (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.